• DOI:10.1016/S0140-6736(17)32758-7
Corpus ID: 46781585

Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial

@article{Mesu2018OralFF,
  title={Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial},
  author={Victor Kande Betu Ku Mesu and Wilfried Mutombo Kalonji and Cl{\'e}lia Bardonneau and Olaf Valverde Mordt and Antoine Tarral},
  journal={The Lancet},
  year={2018},
  volume={391},
  pages={144-154}
}

Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, +2 authors Antoine Tarral

Published 2018

Medicine

The Lancet

BACKGROUND Few therapeutic options are available to treat the late-stage of human African trypanosomiasis, a neglected tropical disease, caused by Trypanosoma brucei gambiense (g-HAT). The firstline treatment is a combination therapy of oral nifurtimox and intravenous eflornithine that needs to be administered in a hospital setting by trained personnel, which is not optimal given that patients often live in remote areas with few health resources. Therefore, we aimed to assess the safety and… CONTINUE READING

View on Elsevier

dndi.org

Save to Library

Create Alert

Cite

Launch Research Feed